Mueller weighs in on when retatrutide might become available and what recent policy changes mean for peptide legality.
Recap by typeshit. Full story at Doctor Michael Mueller.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
2:07:50
A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
An ultramarathoner credits BPC-157 for her recovery while pharmacists warn that 'research use only' products skip key safety checks and human data stays thin.
The doctor says more patients have been coming in over recent years after losing a lot of weight on drugs like Ozempic and Mounjaro.
Loading…